Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glucosamine→

Glucosamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3416-24-8
Molecular formula
C6H13NO5
Molecular weight
179.17 g/mol
Drug class
Amino sugarglycosaminoglycan and cartilage-matrix precursor
Mechanism of action
A substrate for synthesis of glycosaminoglycans and proteoglycans in connective tissue. Oral supplementation has been proposed to influence cartilage metabolism, but a disease-modifying mechanism for osteoarthritis has not been established.
Indications / reported uses
  • Used as a dietary supplement for osteoarthritis symptoms in some countries; not a universally approved disease-modifying treatment, and efficacy evidence is inconsistent

Sources: NCCIH — Glucosamine and chondroitin for osteoarthritis · NLM MeSH — Glucosamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glucosamine Environmental Risk Assessment (ERA) (the Glucosamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.